BioPhausia focuses and sells OTC products to Meda for SEK 190 million
BioPhausia signed an agreement to sell its portfolio of OTC products to Meda for a total of SEK 190 million, plus the
value of the inventory. The Company has also completed the previously communicated strategic review of its generics portfolio, allowing further concentration on prescription ... more
Meda acquires Alaven, a US
specialty pharma company
Meda has signed an agreement to acquire the US specialty pharmaceutical company Alaven. The acquisition will significantly enhance Meda’s marketing capabilities in the US and expand the therapeutic focus to include both gastroenterology and women’s health; areas that Meda already operates i ... more
Meda: Onsolis receives FDA approval
The U.S. Food and Drug Administration (FDA) has approved Onsolis (fentanyl buccal soluble film). This new and patented product is indicated for the management of breakthrough pain in cancer patients who are already receiving and who are tolerant to opioid therapy for their underlying persis ...
more
Companies
Meda AB
Meda is one of Europe's leading specialty pharma companies. Meda covers all of Europe via its subsidiaries in more than 20 European
countries and has more than 1000 employees in marketing and sales. In other world markets, agents and other pharma companies market and sell Meda's pharmaceuti ... more
Meda Pharma S.p.A.
Meda is an international specialty pharma company that covers all of Europe and the US via its subsidiaries
in 26 countries and more than 1500 employees in marketing and sales. In other world markets, agents and other pharma companies market and sell Meda's pharmaceuticals. more
Meda Pharma S.A.U.
Meda is an international specialty pharma company that covers all of Europe and the US via its
subsidiaries in 26 countries and more than 1500 employees in marketing and sales. In other world markets, agents and other pharma companies market and sell Meda's pharmaceuticals. more
